Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Akebia downgraded to Underweight from Neutral at JPMorgan » 09:23
01/29/21
01/29
09:23
01/29/21
09:23
AKBA

Akebia

$3.43 /

-0.065 (-1.86%)

JPMorgan analyst Eric…

JPMorgan analyst Eric Joseph downgraded Akebia to Underweight from Neutral without a price target. The analyst rebalanced ratings across the U.S. SMID biotechnology sector coming away from his firm's Healthcare Conference. Joseph maintains an "overall upbeat outlook" for biotech in 2021 in view of "solid" sector fundamentals, but he sees higher growth opportunities among names with "best-in-class" assets that are either de-risked or approaching pivotal data inside of 6-12 months. Names with lengthier catalyst timelines are likely to trade more in-range with the group despite the potential for substantive value creation longer term, Joseph tells investors in a research note.

ShowHide Related Items >><<
AKBA Akebia
$3.43 /

-0.065 (-1.86%)

AKBA Akebia
$3.43 /

-0.065 (-1.86%)

01/29/21 JPMorgan
Akebia downgraded to Underweight from Neutral at JPMorgan
10/23/20 Piper Sandler
Akebia rally justified as vadadustat has chance, says Piper Sandler
10/23/20 JPMorgan
JPMorgan says Akebia's data 'do little' to restore confidence in NDD approval
09/04/20 RBC Capital
Akebia price target lowered to $5 from $12 at RBC Capital
AKBA Akebia
$3.43 /

-0.065 (-1.86%)

  • 12
    May
AKBA Akebia
$3.43 /

-0.065 (-1.86%)

AKBA Akebia
$3.43 /

-0.065 (-1.86%)

AKBA Akebia
$3.43 /

-0.065 (-1.86%)

Downgrade
Akebia downgraded to Underweight from Neutral at JPMorgan » 05:17
01/29/21
01/29
05:17
01/29/21
05:17
AKBA

Akebia

$3.43 /

-0.065 (-1.86%)

JPMorgan analyst Eric…

JPMorgan analyst Eric Joseph downgraded Akebia Therapeutics to Underweight from Neutral.

ShowHide Related Items >><<
AKBA Akebia
$3.43 /

-0.065 (-1.86%)

AKBA Akebia
$3.43 /

-0.065 (-1.86%)

10/23/20 Piper Sandler
Akebia rally justified as vadadustat has chance, says Piper Sandler
10/23/20 JPMorgan
JPMorgan says Akebia's data 'do little' to restore confidence in NDD approval
09/04/20 RBC Capital
Akebia price target lowered to $5 from $12 at RBC Capital
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
AKBA Akebia
$3.43 /

-0.065 (-1.86%)

  • 12
    May
AKBA Akebia
$3.43 /

-0.065 (-1.86%)

AKBA Akebia
$3.43 /

-0.065 (-1.86%)

AKBA Akebia
$3.43 /

-0.065 (-1.86%)

Conference/Events
Akebia management to meet virtually with Mizuho » 04:55
01/27/21
01/27
04:55
01/27/21
04:55
AKBA

Akebia

$3.77 /

+0.06 (+1.62%)

Virtual Meetings to be…

Virtual Meetings to be held January 26-27 hosted by Mizuho.

ShowHide Related Items >><<
AKBA Akebia
$3.77 /

+0.06 (+1.62%)

AKBA Akebia
$3.77 /

+0.06 (+1.62%)

10/23/20 Piper Sandler
Akebia rally justified as vadadustat has chance, says Piper Sandler
10/23/20 JPMorgan
JPMorgan says Akebia's data 'do little' to restore confidence in NDD approval
09/04/20 RBC Capital
Akebia price target lowered to $5 from $12 at RBC Capital
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
AKBA Akebia
$3.77 /

+0.06 (+1.62%)

  • 12
    May
AKBA Akebia
$3.77 /

+0.06 (+1.62%)

AKBA Akebia
$3.77 /

+0.06 (+1.62%)

AKBA Akebia
$3.77 /

+0.06 (+1.62%)

Conference/Events
Akebia management to meet virtually with Mizuho » 10:46
01/26/21
01/26
10:46
01/26/21
10:46
AKBA

Akebia

$3.73 /

+0.02 (+0.54%)

Virtual Meetings to be…

Virtual Meetings to be held January 26-27 hosted by Mizuho.

ShowHide Related Items >><<
AKBA Akebia
$3.73 /

+0.02 (+0.54%)

AKBA Akebia
$3.73 /

+0.02 (+0.54%)

10/23/20 Piper Sandler
Akebia rally justified as vadadustat has chance, says Piper Sandler
10/23/20 JPMorgan
JPMorgan says Akebia's data 'do little' to restore confidence in NDD approval
09/04/20 RBC Capital
Akebia price target lowered to $5 from $12 at RBC Capital
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
AKBA Akebia
$3.73 /

+0.02 (+0.54%)

  • 12
    May
AKBA Akebia
$3.73 /

+0.02 (+0.54%)

AKBA Akebia
$3.73 /

+0.02 (+0.54%)

AKBA Akebia
$3.73 /

+0.02 (+0.54%)

Over a month ago
Periodicals
Researchers awarded funding to expand Akebia drug trial, UTHealth News says » 12:13
01/13/21
01/13
12:13
01/13/21
12:13
AKBA

Akebia

$2.99 /

-0.05 (-1.64%)

Researchers have received…

Researchers have received funding from the Department of Defense to expand the Phase II clinical trial of vadadustat, a drug being developed by Akebia that could help prevent acute respiratory distress syndrome in Covid-19 patients, at The University of Texas Health Science Center at Houston, UTHealth News' Amy Laukka reports. The award was given through the DOD's Peer Reviewed Medical Research Program as a COVID Clinical Trial Award, according to the report. Akebia recently completed its global Phase III clinical trial development for the treatment of anemia due to chronic kidney disease in patients on dialysis and not on dialysis. Reference Link

ShowHide Related Items >><<
AKBA Akebia
$2.99 /

-0.05 (-1.64%)

AKBA Akebia
$2.99 /

-0.05 (-1.64%)

10/23/20 Piper Sandler
Akebia rally justified as vadadustat has chance, says Piper Sandler
10/23/20 JPMorgan
JPMorgan says Akebia's data 'do little' to restore confidence in NDD approval
09/04/20 RBC Capital
Akebia price target lowered to $5 from $12 at RBC Capital
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
AKBA Akebia
$2.99 /

-0.05 (-1.64%)

  • 12
    May
AKBA Akebia
$2.99 /

-0.05 (-1.64%)

AKBA Akebia
$2.99 /

-0.05 (-1.64%)

Over a quarter ago
Hot Stocks
Akebia reports manuscript on global Phase 3 INNO2VATE program rationale » 08:32
11/16/20
11/16
08:32
11/16/20
08:32
AKBA

Akebia

$2.53 /

+0.055 (+2.22%)

Akebia Therapeutics…

Akebia Therapeutics announced the publication of a manuscript detailing the study design and methodology for its global Phase 3 INNO2VATE program in Nephrology Dialysis Transplantation, the official journal for the European Renal Association-European Dialysis and Transplant Association. The publication of Akebia's manuscript in NDT marks the first publication in a peer-reviewed journal related to a global Phase 3 program of an oral hypoxia-inducible factor prolyl hydroxylase inhibitor being evaluated as a potential treatment for anemia due to chronic kidney disease. The manuscript, titled "Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials," includes a detailed description of design and methodology of the two Phase 3 INNO2VATE trials and summarize demographic and baseline characteristics of randomized patients. Importantly, the manuscript notes that "demographics and baseline characteristics of patients enrolled in the two studies are comparable to those typically observed in patients with DD-CKD, suggesting the results of the INNO2VATE studies will be generalizable to a large proportion of the DD-CKD population." INNO2VATE evaluated the efficacy and safety of vadadustat, Akebia's investigational oral HIF-PHI, versus darbepoetin alfa for the treatment of anemia due to CKD in adult patients on dialysis. As previously reported, vadadustat achieved the primary and key secondary efficacy endpoints and the primary safety endpoint of the INNO2VATE program, defined as non-inferiority of vadadustat versus darbepoetin alfa in time to first occurrence of a major adverse cardiovascular event, which is the composite of all-cause mortality, non-fatal myocardial infarction, or non-fatal stroke across both INNO2VATE studies.

ShowHide Related Items >><<
AKBA Akebia
$2.53 /

+0.055 (+2.22%)

AKBA Akebia
$2.53 /

+0.055 (+2.22%)

10/23/20 Piper Sandler
Akebia rally justified as vadadustat has chance, says Piper Sandler
10/23/20 JPMorgan
JPMorgan says Akebia's data 'do little' to restore confidence in NDD approval
09/04/20 RBC Capital
Akebia price target lowered to $5 from $12 at RBC Capital
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
AKBA Akebia
$2.53 /

+0.055 (+2.22%)

  • 12
    May
AKBA Akebia
$2.53 /

+0.055 (+2.22%)

AKBA Akebia
$2.53 /

+0.055 (+2.22%)

Earnings
Akebia reports Q3 EPS (42c), consensus (17c) » 08:50
11/05/20
11/05
08:50
11/05/20
08:50
AKBA

Akebia

$2.56 /

+0.135 (+5.58%)

Reports Q3 revenue…

Reports Q3 revenue $60.0M, consensus $84.9M. "We recently completed our pre-NDA meeting with the FDA. This was an important milestone for our vadadustat development program, and we remain on track to submit an NDA to the FDA as early as possible next year. A key component of this NDA is the positive data from our global Phase 3 INNO2VATE program for the treatment of anemia due to CKD in adult patients on dialysis, which we shared most recently at ASN Kidney Week. These data were clear and consistent, and showed that vadadustat achieved both the primary and key secondary efficacy endpoints, as well as the primary and key secondary safety endpoints of the program for patients on dialysis. Based on our pre-NDA meeting, we remain confident that these results support the potential approval of vadadustat for the treatment of anemia due to CKD in adult patients on dialysis," said CEO John Butler. "Subject to regulatory review and approval, we believe vadadustat has the potential to be a new oral standard of care to help address the unmet needs of adult patients on dialysis, including both incident and prevalent dialysis patients. We believe this could translate into a potential $2B market opportunity in the U.S., alone. Together with our collaborator, Otsuka, we look forward to bringing this innovative therapy to patients on dialysis globally, if approved."

ShowHide Related Items >><<
AKBA Akebia
$2.56 /

+0.135 (+5.58%)

AKBA Akebia
$2.56 /

+0.135 (+5.58%)

10/23/20 Piper Sandler
Akebia rally justified as vadadustat has chance, says Piper Sandler
10/23/20 JPMorgan
JPMorgan says Akebia's data 'do little' to restore confidence in NDD approval
09/04/20 RBC Capital
Akebia price target lowered to $5 from $12 at RBC Capital
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
AKBA Akebia
$2.56 /

+0.135 (+5.58%)

  • 12
    May
AKBA Akebia
$2.56 /

+0.135 (+5.58%)

AKBA Akebia
$2.56 /

+0.135 (+5.58%)

AKBA Akebia
$2.56 /

+0.135 (+5.58%)

Conference/Events
American Society of Nephrology to hold virtual annual meeting » 04:55
10/25/20
10/25
04:55
10/25/20
04:55
AKBA

Akebia

$3.18 /

-0.065 (-2.01%)

, ALNY

Alnylam

$131.62 /

-2.7 (-2.01%)

, ALPMY

Astellas Pharma

$0.00 /

+ (+0.00%)

, AMGN

Amgen

$227.06 /

-0.84 (-0.37%)

, AZN

AstraZeneca

$52.01 /

+0.03 (+0.06%)

, BAX

Baxter

$81.08 /

-0.35 (-0.43%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BD

Budget Group

$0.00 /

+ (+0.00%)

, CALT

Calliditas Therapeutics

$26.00 /

-1.16 (-4.27%)

, ICUI

ICU Medical

$192.47 /

-2.01 (-1.03%)

, TCDA

Tricida

$8.74 /

-0.17 (-1.91%)

, SNY

Sanofi

$49.33 /

+0.39 (+0.80%)

, GSK

GlaxoSmithKline

$35.30 /

+0.22 (+0.63%)

, FOLD

Amicus

$18.48 /

+0.455 (+2.52%)

, FMS

Fresenius Medical

$40.87 /

+0.75 (+1.87%)

, DRNA

Dicerna

$19.38 /

-0.32 (-1.62%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, CCXI

ChemoCentryx

$58.92 /

+3.93 (+7.15%)

, KDNY

Chinook Therapeutics

$15.34 /

-0.1 (-0.65%)

, RTRX

Retrophin

$20.91 /

-0.12 (-0.57%)

, OMER

Omeros

$10.66 /

-0.4 (-3.62%)

, OM

Outset Medical

$50.00 /

+1.8 (+3.73%)

, NVS

Novartis

$84.41 /

-0.04 (-0.05%)

, VRTX

Vertex Pharmaceuticals

$211.52 /

+1.34 (+0.64%)

Kidney Week 2020: Virtual…

Kidney Week 2020: Virtual Annual Meeting will be held on October 19-25. Webcast Link

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

TCDA Tricida
$8.74 /

-0.17 (-1.91%)

SNY Sanofi
$49.33 /

+0.39 (+0.80%)

RTRX Retrophin
$20.91 /

-0.12 (-0.57%)

OMER Omeros
$10.66 /

-0.4 (-3.62%)

NVS Novartis
$84.41 /

-0.04 (-0.05%)

KDNY Chinook Therapeutics
$15.34 /

-0.1 (-0.65%)

ICUI ICU Medical
$192.47 /

-2.01 (-1.03%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

FOLD Amicus
$18.48 /

+0.455 (+2.52%)

FMS Fresenius Medical
$40.87 /

+0.75 (+1.87%)

DRNA Dicerna
$19.38 /

-0.32 (-1.62%)

CCXI ChemoCentryx
$58.92 /

+3.93 (+7.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.08 /

-0.35 (-0.43%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

ALNY Alnylam
$131.62 /

-2.7 (-2.01%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

10/23/20 Piper Sandler
Akebia rally justified as vadadustat has chance, says Piper Sandler
10/23/20 JPMorgan
JPMorgan says Akebia's data 'do little' to restore confidence in NDD approval
09/04/20 RBC Capital
Akebia price target lowered to $5 from $12 at RBC Capital
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
ALNY Alnylam
$131.62 /

-2.7 (-2.01%)

09/30/20 Berenberg
Alnylam reinitiated with a Hold at Berenberg
09/08/20 Citi
Alnylam initiated with a Buy at Citi
08/11/20 Oppenheimer
Alnylam downgraded to Perform on valuation at Oppenheimer
08/11/20 Oppenheimer
Alnylam downgraded to Perform from Outperform at Oppenheimer
ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy from Neutral at Goldman Sachs
01/23/20 Morgan Stanley
Astellas Pharma resumed with an Overweight at Morgan Stanley
AMGN Amgen
$227.06 /

-0.84 (-0.37%)

10/22/20 Oppenheimer
Amgen price target lowered to $275 from $280 at Oppenheimer
10/09/20
Fly Intel: Top five analyst downgrades
10/09/20 Truist
Amgen downgraded to Hold from Buy at Truist
10/09/20 Bernstein
Amgen downgraded to Market Perform from Outperform at Bernstein
AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
10/08/20 JPMorgan
AstraZeneca FY20 guide could look conservative after Q3 results, says JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
09/29/20 Berenberg
AstraZeneca initiated with a Buy at Berenberg
BAX Baxter
$81.08 /

-0.35 (-0.43%)

10/08/20 Goldman Sachs
Baxter pump delays speak more to FDA protocols than actual product, says Goldman
10/08/20 Piper Sandler
Baxter 510k submission withdrawal 'disappointing,' 'not surprising,' says Piper
10/08/20 KeyBanc
Investors will view Baxter pump news 'somewhat negatively,' says KeyBanc
10/01/20
Fly Intel: Top five analyst upgrades
BAYRY Bayer
$0.00 /

+ (+0.00%)

10/21/20 Morgan Stanley
Bayer price target lowered to EUR 68 from EUR 82 at Morgan Stanley
10/13/20 Barclays
Bayer downgraded to Equal Weight from Overweight at Barclays
10/08/20 Kepler Cheuvreux
Bayer upgraded to Buy from Hold at Kepler Cheuvreux
10/05/20 UBS
Bayer price target lowered to EUR 85 from EUR 110 at UBS
BD Budget Group
$0.00 /

+ (+0.00%)

CALT Calliditas Therapeutics
$26.00 /

-1.16 (-4.27%)

07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
ICUI ICU Medical
$192.47 /

-2.01 (-1.03%)

09/02/20 KeyBanc
ICU Medical price target raised to $218 from $199 at KeyBanc
05/13/20 KeyBanc
ICU Medical price target lowered to $199 from $206 at KeyBanc
03/18/20 KeyBanc
ICU Medical upgraded to Overweight from Sector Weight at KeyBanc
11/12/19 Raymond James
ICU Medical price target raised to $203 from $185 at Raymond James
TCDA Tricida
$8.74 /

-0.17 (-1.91%)

09/29/20 JPMorgan
Tricida resumed with an Underweight at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Needham
Tricida price target lowered to $20 from $44 at Needham
08/25/20 Goldman Sachs
Tricida downgraded to Neutral from Buy at Goldman Sachs
SNY Sanofi
$49.33 /

+0.39 (+0.80%)

10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
09/29/20 Berenberg
Sanofi initiated with a Hold at Berenberg
09/21/20 Piper Sandler
Regeneron's Libtayo delivered results on par with Keytruda, says Piper Sandler
GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

10/15/20 SVB Leerink
SVB Leerink sees possible opportunity for Amarin to 'salvage Vascepa' in U.S.
10/12/20 UBS
GlaxoSmithKline price target lowered to 1,730 GBp from 1,800 GBp at UBS
10/09/20 Morgan Stanley
GlaxoSmithKline price target lowered to 1,695 GBp from 1,700 GBp at Morgan Stanley
10/08/20 JPMorgan
JPMorgan backs Neutral on GSK ahead of Q3 results
FOLD Amicus
$18.48 /

+0.455 (+2.52%)

08/11/20 Citi
Amicus price target raised to $20 from $15 at Citi
06/16/20 BTIG
Amicus initiated with a Buy at BTIG
06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/09/20 Citi
Amicus shares worth $10 on Galafold alone, says Citi
FMS Fresenius Medical
$40.87 /

+0.75 (+1.87%)

10/13/20 Deutsche Bank
Fresenius Medical price target lowered to EUR 97 from EUR 100 at Deutsche Bank
08/18/20 Morgan Stanley
Fresenius Medical price target raised to EUR 76 from EUR 70 at Morgan Stanley
08/05/20 Jefferies
Fresenius Medical downgraded to Hold from Buy at Jefferies
07/28/20 Berenberg
Fresenius Medical price target raised to EUR 94.85 from EUR 88.25 at Berenberg
DRNA Dicerna
$19.38 /

-0.32 (-1.62%)

08/07/20 H.C. Wainwright
Dicerna price target raised to $35 from $32 at H.C. Wainwright
07/01/20 Baird
Dicerna elevated to Fresh Pick at Baird
05/12/20 RBC Capital
Dicerna initiated with an Outperform at RBC Capital
05/11/20 Truist
Dicerna price target raised to $33 from $28 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

CCXI ChemoCentryx
$58.92 /

+3.93 (+7.15%)

09/17/20 H.C. Wainwright
ChemoCentryx price target raised to $85 from $73 at H.C. Wainwright
09/17/20 Piper Sandler
ChemoCentryx target lowered to $67 at Piper Sandler on lower avacopan AAV sales
08/12/20 SVB Leerink
ChemoCentryx price target raised to $75 from $65 at SVB Leerink
07/09/20 Piper Sandler
ChemoCentryx submits NDA for avacopan in AAV to FDA, says Piper Sandler
KDNY Chinook Therapeutics
$15.34 /

-0.1 (-0.65%)

10/20/20 Oppenheimer
Chinook Therapeutics upgraded to Outperform from Perform at Oppenheimer
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
RTRX Retrophin
$20.91 /

-0.12 (-0.57%)

09/17/20 Wedbush
Wedbush starts Retrophin at Outperform ahead of 'value-creating catalysts'
09/17/20 Wedbush
Retrophin initiated with an Outperform at Wedbush
08/24/20 BofA
Retrophin initiated with a Buy at BofA
07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
OMER Omeros
$10.66 /

-0.4 (-3.62%)

10/20/20 BofA
Omeros initiated with a Buy at BofA
10/20/20 BofA
Omeros initiated with a Buy at BofA
09/01/20 Wedbush
Omeros price target lowered to $12 from $17 at Wedbush
08/21/20 H.C. Wainwright
Omeros price target lowered to $32 from $34 at H.C. Wainwright
OM Outset Medical
$50.00 /

+1.8 (+3.73%)

10/12/20
Fly Intel: Top five analyst initiations
10/12/20 Morgan Stanley
Outset Medical initiated with an Equal Weight at Morgan Stanley
10/12/20 Stifel
Outset Medical initiated with a Buy at Stifel
10/12/20 SVB Leerink
Outset Medical initiated with a Market Perform at SVB Leerink
NVS Novartis
$84.41 /

-0.04 (-0.05%)

09/29/20 Berenberg
Novartis initiated with a Buy at Berenberg
09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
09/23/20 BMO Capital
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

10/15/20 Truist
Vertex Pharmaceuticals price target lowered to $305 from $330 at Truist
10/15/20 Morgan Stanley
VX-814 discontinuation can drive Vertex shares 5%-10% lower, says Morgan Stanley
10/15/20 JPMorgan
Vertex pipeline setback a 'major disappointment,' says JPMorgan
10/15/20 Citi
Vertex selloff on VX-814 news a buying opportunity, says Citi
VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

TCDA Tricida
$8.74 /

-0.17 (-1.91%)

SNY Sanofi
$49.33 /

+0.39 (+0.80%)

RTRX Retrophin
$20.91 /

-0.12 (-0.57%)

OMER Omeros
$10.66 /

-0.4 (-3.62%)

NVS Novartis
$84.41 /

-0.04 (-0.05%)

ICUI ICU Medical
$192.47 /

-2.01 (-1.03%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

FOLD Amicus
$18.48 /

+0.455 (+2.52%)

DRNA Dicerna
$19.38 /

-0.32 (-1.62%)

CCXI ChemoCentryx
$58.92 /

+3.93 (+7.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.08 /

-0.35 (-0.43%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

ALNY Alnylam
$131.62 /

-2.7 (-2.01%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

  • 15
    Sep
  • 12
    Aug
  • 11
    Jun
  • 09
    Jun
  • 05
    Jun
  • 12
    May
  • 05
    Dec
SNY Sanofi
$49.33 /

+0.39 (+0.80%)

NVS Novartis
$84.41 /

-0.04 (-0.05%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

FOLD Amicus
$18.48 /

+0.455 (+2.52%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

TCDA Tricida
$8.74 /

-0.17 (-1.91%)

SNY Sanofi
$49.33 /

+0.39 (+0.80%)

OMER Omeros
$10.66 /

-0.4 (-3.62%)

OM Outset Medical
$50.00 /

+1.8 (+3.73%)

NVS Novartis
$84.41 /

-0.04 (-0.05%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

CCXI ChemoCentryx
$58.92 /

+3.93 (+7.15%)

CALT Calliditas Therapeutics
$26.00 /

-1.16 (-4.27%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.08 /

-0.35 (-0.43%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

ALNY Alnylam
$131.62 /

-2.7 (-2.01%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

KDNY Chinook Therapeutics
$15.34 /

-0.1 (-0.65%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

Conference/Events
American Society of Nephrology to hold virtual annual meeting » 04:55
10/24/20
10/24
04:55
10/24/20
04:55
AKBA

Akebia

$3.18 /

-0.065 (-2.01%)

, ALNY

Alnylam

$131.62 /

-2.7 (-2.01%)

, ALPMY

Astellas Pharma

$0.00 /

+ (+0.00%)

, AMGN

Amgen

$227.06 /

-0.84 (-0.37%)

, AZN

AstraZeneca

$52.01 /

+0.03 (+0.06%)

, BAX

Baxter

$81.08 /

-0.35 (-0.43%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BD

Budget Group

$0.00 /

+ (+0.00%)

, CALT

Calliditas Therapeutics

$26.00 /

-1.16 (-4.27%)

, ICUI

ICU Medical

$192.47 /

-2.01 (-1.03%)

, TCDA

Tricida

$8.74 /

-0.17 (-1.91%)

, SNY

Sanofi

$49.33 /

+0.39 (+0.80%)

, GSK

GlaxoSmithKline

$35.30 /

+0.22 (+0.63%)

, FOLD

Amicus

$18.48 /

+0.455 (+2.52%)

, FMS

Fresenius Medical

$40.87 /

+0.75 (+1.87%)

, DRNA

Dicerna

$19.38 /

-0.32 (-1.62%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, CCXI

ChemoCentryx

$58.92 /

+3.93 (+7.15%)

, KDNY

Chinook Therapeutics

$15.34 /

-0.1 (-0.65%)

, RTRX

Retrophin

$20.91 /

-0.12 (-0.57%)

, OMER

Omeros

$10.66 /

-0.4 (-3.62%)

, OM

Outset Medical

$50.00 /

+1.8 (+3.73%)

, NVS

Novartis

$84.41 /

-0.04 (-0.05%)

, VRTX

Vertex Pharmaceuticals

$211.52 /

+1.34 (+0.64%)

Kidney Week 2020: Virtual…

Kidney Week 2020: Virtual Annual Meeting will be held on October 19-25. Webcast Link

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

TCDA Tricida
$8.74 /

-0.17 (-1.91%)

SNY Sanofi
$49.33 /

+0.39 (+0.80%)

RTRX Retrophin
$20.91 /

-0.12 (-0.57%)

OMER Omeros
$10.66 /

-0.4 (-3.62%)

NVS Novartis
$84.41 /

-0.04 (-0.05%)

KDNY Chinook Therapeutics
$15.34 /

-0.1 (-0.65%)

ICUI ICU Medical
$192.47 /

-2.01 (-1.03%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

FOLD Amicus
$18.48 /

+0.455 (+2.52%)

FMS Fresenius Medical
$40.87 /

+0.75 (+1.87%)

DRNA Dicerna
$19.38 /

-0.32 (-1.62%)

CCXI ChemoCentryx
$58.92 /

+3.93 (+7.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.08 /

-0.35 (-0.43%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

ALNY Alnylam
$131.62 /

-2.7 (-2.01%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

10/23/20 Piper Sandler
Akebia rally justified as vadadustat has chance, says Piper Sandler
10/23/20 JPMorgan
JPMorgan says Akebia's data 'do little' to restore confidence in NDD approval
09/04/20 RBC Capital
Akebia price target lowered to $5 from $12 at RBC Capital
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
ALNY Alnylam
$131.62 /

-2.7 (-2.01%)

09/30/20 Berenberg
Alnylam reinitiated with a Hold at Berenberg
09/08/20 Citi
Alnylam initiated with a Buy at Citi
08/11/20 Oppenheimer
Alnylam downgraded to Perform on valuation at Oppenheimer
08/11/20 Oppenheimer
Alnylam downgraded to Perform from Outperform at Oppenheimer
ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy from Neutral at Goldman Sachs
01/23/20 Morgan Stanley
Astellas Pharma resumed with an Overweight at Morgan Stanley
AMGN Amgen
$227.06 /

-0.84 (-0.37%)

10/22/20 Oppenheimer
Amgen price target lowered to $275 from $280 at Oppenheimer
10/09/20
Fly Intel: Top five analyst downgrades
10/09/20 Truist
Amgen downgraded to Hold from Buy at Truist
10/09/20 Bernstein
Amgen downgraded to Market Perform from Outperform at Bernstein
AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
10/08/20 JPMorgan
AstraZeneca FY20 guide could look conservative after Q3 results, says JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
09/29/20 Berenberg
AstraZeneca initiated with a Buy at Berenberg
BAX Baxter
$81.08 /

-0.35 (-0.43%)

10/08/20 Goldman Sachs
Baxter pump delays speak more to FDA protocols than actual product, says Goldman
10/08/20 Piper Sandler
Baxter 510k submission withdrawal 'disappointing,' 'not surprising,' says Piper
10/08/20 KeyBanc
Investors will view Baxter pump news 'somewhat negatively,' says KeyBanc
10/01/20
Fly Intel: Top five analyst upgrades
BAYRY Bayer
$0.00 /

+ (+0.00%)

10/21/20 Morgan Stanley
Bayer price target lowered to EUR 68 from EUR 82 at Morgan Stanley
10/13/20 Barclays
Bayer downgraded to Equal Weight from Overweight at Barclays
10/08/20 Kepler Cheuvreux
Bayer upgraded to Buy from Hold at Kepler Cheuvreux
10/05/20 UBS
Bayer price target lowered to EUR 85 from EUR 110 at UBS
BD Budget Group
$0.00 /

+ (+0.00%)

CALT Calliditas Therapeutics
$26.00 /

-1.16 (-4.27%)

07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
ICUI ICU Medical
$192.47 /

-2.01 (-1.03%)

09/02/20 KeyBanc
ICU Medical price target raised to $218 from $199 at KeyBanc
05/13/20 KeyBanc
ICU Medical price target lowered to $199 from $206 at KeyBanc
03/18/20 KeyBanc
ICU Medical upgraded to Overweight from Sector Weight at KeyBanc
11/12/19 Raymond James
ICU Medical price target raised to $203 from $185 at Raymond James
TCDA Tricida
$8.74 /

-0.17 (-1.91%)

09/29/20 JPMorgan
Tricida resumed with an Underweight at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Needham
Tricida price target lowered to $20 from $44 at Needham
08/25/20 Goldman Sachs
Tricida downgraded to Neutral from Buy at Goldman Sachs
SNY Sanofi
$49.33 /

+0.39 (+0.80%)

10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
09/29/20 Berenberg
Sanofi initiated with a Hold at Berenberg
09/21/20 Piper Sandler
Regeneron's Libtayo delivered results on par with Keytruda, says Piper Sandler
GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

10/15/20 SVB Leerink
SVB Leerink sees possible opportunity for Amarin to 'salvage Vascepa' in U.S.
10/12/20 UBS
GlaxoSmithKline price target lowered to 1,730 GBp from 1,800 GBp at UBS
10/09/20 Morgan Stanley
GlaxoSmithKline price target lowered to 1,695 GBp from 1,700 GBp at Morgan Stanley
10/08/20 JPMorgan
JPMorgan backs Neutral on GSK ahead of Q3 results
FOLD Amicus
$18.48 /

+0.455 (+2.52%)

08/11/20 Citi
Amicus price target raised to $20 from $15 at Citi
06/16/20 BTIG
Amicus initiated with a Buy at BTIG
06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/09/20 Citi
Amicus shares worth $10 on Galafold alone, says Citi
FMS Fresenius Medical
$40.87 /

+0.75 (+1.87%)

10/13/20 Deutsche Bank
Fresenius Medical price target lowered to EUR 97 from EUR 100 at Deutsche Bank
08/18/20 Morgan Stanley
Fresenius Medical price target raised to EUR 76 from EUR 70 at Morgan Stanley
08/05/20 Jefferies
Fresenius Medical downgraded to Hold from Buy at Jefferies
07/28/20 Berenberg
Fresenius Medical price target raised to EUR 94.85 from EUR 88.25 at Berenberg
DRNA Dicerna
$19.38 /

-0.32 (-1.62%)

08/07/20 H.C. Wainwright
Dicerna price target raised to $35 from $32 at H.C. Wainwright
07/01/20 Baird
Dicerna elevated to Fresh Pick at Baird
05/12/20 RBC Capital
Dicerna initiated with an Outperform at RBC Capital
05/11/20 Truist
Dicerna price target raised to $33 from $28 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

CCXI ChemoCentryx
$58.92 /

+3.93 (+7.15%)

09/17/20 H.C. Wainwright
ChemoCentryx price target raised to $85 from $73 at H.C. Wainwright
09/17/20 Piper Sandler
ChemoCentryx target lowered to $67 at Piper Sandler on lower avacopan AAV sales
08/12/20 SVB Leerink
ChemoCentryx price target raised to $75 from $65 at SVB Leerink
07/09/20 Piper Sandler
ChemoCentryx submits NDA for avacopan in AAV to FDA, says Piper Sandler
KDNY Chinook Therapeutics
$15.34 /

-0.1 (-0.65%)

10/20/20 Oppenheimer
Chinook Therapeutics upgraded to Outperform from Perform at Oppenheimer
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
RTRX Retrophin
$20.91 /

-0.12 (-0.57%)

09/17/20 Wedbush
Wedbush starts Retrophin at Outperform ahead of 'value-creating catalysts'
09/17/20 Wedbush
Retrophin initiated with an Outperform at Wedbush
08/24/20 BofA
Retrophin initiated with a Buy at BofA
07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
OMER Omeros
$10.66 /

-0.4 (-3.62%)

10/20/20 BofA
Omeros initiated with a Buy at BofA
10/20/20 BofA
Omeros initiated with a Buy at BofA
09/01/20 Wedbush
Omeros price target lowered to $12 from $17 at Wedbush
08/21/20 H.C. Wainwright
Omeros price target lowered to $32 from $34 at H.C. Wainwright
OM Outset Medical
$50.00 /

+1.8 (+3.73%)

10/12/20
Fly Intel: Top five analyst initiations
10/12/20 Morgan Stanley
Outset Medical initiated with an Equal Weight at Morgan Stanley
10/12/20 Stifel
Outset Medical initiated with a Buy at Stifel
10/12/20 SVB Leerink
Outset Medical initiated with a Market Perform at SVB Leerink
NVS Novartis
$84.41 /

-0.04 (-0.05%)

09/29/20 Berenberg
Novartis initiated with a Buy at Berenberg
09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
09/23/20 BMO Capital
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

10/15/20 Truist
Vertex Pharmaceuticals price target lowered to $305 from $330 at Truist
10/15/20 Morgan Stanley
VX-814 discontinuation can drive Vertex shares 5%-10% lower, says Morgan Stanley
10/15/20 JPMorgan
Vertex pipeline setback a 'major disappointment,' says JPMorgan
10/15/20 Citi
Vertex selloff on VX-814 news a buying opportunity, says Citi
VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

TCDA Tricida
$8.74 /

-0.17 (-1.91%)

SNY Sanofi
$49.33 /

+0.39 (+0.80%)

RTRX Retrophin
$20.91 /

-0.12 (-0.57%)

OMER Omeros
$10.66 /

-0.4 (-3.62%)

NVS Novartis
$84.41 /

-0.04 (-0.05%)

ICUI ICU Medical
$192.47 /

-2.01 (-1.03%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

FOLD Amicus
$18.48 /

+0.455 (+2.52%)

DRNA Dicerna
$19.38 /

-0.32 (-1.62%)

CCXI ChemoCentryx
$58.92 /

+3.93 (+7.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.08 /

-0.35 (-0.43%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

ALNY Alnylam
$131.62 /

-2.7 (-2.01%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

  • 15
    Sep
  • 12
    Aug
  • 11
    Jun
  • 09
    Jun
  • 05
    Jun
  • 12
    May
  • 05
    Dec
SNY Sanofi
$49.33 /

+0.39 (+0.80%)

NVS Novartis
$84.41 /

-0.04 (-0.05%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

FOLD Amicus
$18.48 /

+0.455 (+2.52%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

TCDA Tricida
$8.74 /

-0.17 (-1.91%)

SNY Sanofi
$49.33 /

+0.39 (+0.80%)

OMER Omeros
$10.66 /

-0.4 (-3.62%)

OM Outset Medical
$50.00 /

+1.8 (+3.73%)

NVS Novartis
$84.41 /

-0.04 (-0.05%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

CCXI ChemoCentryx
$58.92 /

+3.93 (+7.15%)

CALT Calliditas Therapeutics
$26.00 /

-1.16 (-4.27%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.08 /

-0.35 (-0.43%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

ALNY Alnylam
$131.62 /

-2.7 (-2.01%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

SNY Sanofi
$49.33 /

+0.39 (+0.80%)

KDNY Chinook Therapeutics
$15.34 /

-0.1 (-0.65%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

Recommendations
Akebia rally justified as vadadustat has chance, says Piper Sandler » 14:17
10/23/20
10/23
14:17
10/23/20
14:17
AKBA

Akebia

$3.24 /

+ (+0.00%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond keeps an Overweight rating on Akebia Therapeutics with an $8 price target upon seeing the full PRO2TECT data. As suspected, geographic differences, specifically targeting higher Hb levels in Europe, drove the result of the primary major adverse cardiovascular events endpoint to miss on non-inferiority, Raymond tells investors in a research note titled "So You're Telling Me There's a Chance." The analyst says that while Akebia will be asking FDA to "squint while reviewing this application, a pathway does seem viable." With the shares seeming to discount the regulatory pathway entirely, today's rally is justified, contends Raymond. The analyst expects continued share upside into a regulatory decision.

ShowHide Related Items >><<
AKBA Akebia
$3.24 /

+ (+0.00%)

AKBA Akebia
$3.24 /

+ (+0.00%)

10/23/20 JPMorgan
JPMorgan says Akebia's data 'do little' to restore confidence in NDD approval
09/04/20 RBC Capital
Akebia price target lowered to $5 from $12 at RBC Capital
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
09/04/20 BTIG
Akebia price target lowered to $6 from $26 at BTIG
AKBA Akebia
$3.24 /

+ (+0.00%)

  • 12
    May
AKBA Akebia
$3.24 /

+ (+0.00%)

AKBA Akebia
$3.24 /

+ (+0.00%)

AKBA Akebia
$3.24 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.